These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8197933)

  • 1. Androcur 50 in the treatment of prostatic carcinoma. Belgian multicentric study with the participation of 30 urologists.
    Peetermans C; Roux E
    Acta Urol Belg; 1994 Apr; 62(1):77-82. PubMed ID: 8197933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cyproterone acetate (Androcur-depo) in the treatment of inoperable prostatic cancer].
    Stepanov VN; Goriunov VG; Chechenin MG; Sivkov AV; Gubdurakhmanov II
    Urol Nefrol (Mosk); 1995; (6):33-6. PubMed ID: 8686122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
    Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
    J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring.
    Green HJ; Pakenham KI; Headley BC; Gardiner RA
    Psychooncology; 2002; 11(5):401-14. PubMed ID: 12228873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life among patients with metastatic prostate cancer.
    Albertsen PC; Aaronson NK; Muller MJ; Keller SD; Ware JE
    Urology; 1997 Feb; 49(2):207-16; discussion 216-7. PubMed ID: 9037282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
    Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hot flashes after orchiectomy in treatment of prostate cancer-- a serious side effect].
    Buchholz NP; Mattarelli G
    Z Gerontol; 1994; 27(5):334-6. PubMed ID: 7528960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
    Schröder FH; Whelan P; de Reijke TM; Kurth KH; Pavone-Macaluso M; Mattelaer J; van Velthoven RF; Debois M; Collette L;
    Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study.
    Schröder FH; Kurth KH; Fosså SD; Hoekstra W; Karthaus PP; Debois M; Collette L;
    J Urol; 2004 Sep; 172(3):923-7. PubMed ID: 15310999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image.
    Issa MM; Lendvay TS; Bouet R; Young MR; Petros JA; Marshall FF
    J Urol; 2005 Sep; 174(3):893-7. PubMed ID: 16093982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.